Pharma is slow, complicated and tangled in regulatory approvals and compliances. But, consumer healthcare is fast moving, has far fewer rules and enjoys better margins. Under the umbrella of consumer healthcare you will find a plethora of categories and products – all of which claim to improve some aspect of health or well being. Think supplements, or over the counter medications like Crocin or Sanofi’s own Allegra, even things like protein bars. 

These are products that you can toss into your shopping cart and purchase without the hassle of a prescription. 

Last year, Sanofi India decided to demerge its consumer arm and list it as a separate entity – Sanofi Consumer Healthcare. Sanofi even gave it a shiny new label: FMCH, or fast-moving consumer healthcare. And this approach seems to be working out well for the French company. Sanofi Consumer Healthcare has been picking up some of the slack. By Q1 of 2024, it was already contributing 30 per cent of Sanofi SA’s total sales and -40 per cent of its operating profit. 

But Sanofi didn’t invent this move. Zydus Lifesciences figured it out back in 2008 when it created Zydus Wellness, the entity behind Sugarfree and Glucon-D. And after that, we saw giants like GSK and Johnson & Johnson follow suit. But here’s the thing about Sanofi. Unlike Zydus, which clearly separates its pharma and consumer-health businesses, Sanofi blurs the line. A lot of its pharmaceutical products are being recategorized and sold as consumer care. 

Tune in.

Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.